AstraZeneca Collaborates with mAbxience to Produce COVID-19 Vaccine in Latin America

 AstraZeneca Collaborates with mAbxience to Produce COVID-19 Vaccine in Latin America

AstraZeneca Collaborates with mAbxience to Produce COVID-19 Vaccine in Latin America

Shots:

  • mAbxience will produce ~200M + doses of AZD1222 and will supply it to all Latin American countries, except Brazil
  • The company will produce API in its facility located in Garín (Argentina) and will send it to Mexico to complete the production and filling process. AstraZeneca will transfer its technology to the Garín plant shortly, allowing the facility to produce the vaccine in the coming months
  • AstraZeneca’s AZD1222 has demonstrated robust immune response in its P-I & II studies, being evaluated in P-III study with its expected completion in the coming months. The vaccine is expected to be available in the H1’21, upon completion of the P-III trial and approval

Click here ­to­ read full press release/ article | Ref: mAbxience | Image: Thailand Medical News

Related News: AstraZeneca to Initiate Production of its COVID-19 Vaccine Early in 2021

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post